BASEL, Switzerland and CAMBRIDGE, Mass., Oct. 18, 2016 (GLOBE NEWSWIRE) — CRISPR Therapeutics AG (Nasdaq:CRSP), a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines, today announced the pricing of its initial public offering of 4,000,000 common shares at a public offering price of $14.00 per share. In addition, CRISPR Therapeutics has granted the underwriters a 30-day option to purchase up to 600,000 additional common shares at the initial public offering price, less the underwriting discounts and commissions. CRISPR Therapeutics’ common shares are expected to begin trading on the NASDAQ Global Market under the ticker symbol “CRSP” on October 19, 2016. The offering is expected to close on October 24, 2016, subject to customary closing conditions.

Citigroup, Piper Jaffray and Barclays are acting as joint book-running managers for the offering. Guggenheim Securities is acting as co-manager.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform.